Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FG Troches Meiji is a combination antibiotic lozenge containing fradiomycin sulfate and gramicidin. It is indicated for the local treatment of various inflammatory conditions of the oral cavity and throat caused by susceptible bacteria, including pharyngitis, tonsillitis, stomatitis, and gingivitis. It is also used prophylactically to prevent infections following dental or oral surgical procedures. Fradiomycin, an aminoglycoside antibiotic, exerts its effect by binding to the bacterial 30S ribosomal subunit and inhibiting protein synthesis. Gramicidin, a polypeptide antibiotic, acts as an ionophore that increases the permeability of the bacterial cell membrane to monovalent cations, disrupting the electrochemical gradient and leading to cell lysis. The product is manufactured by PT Meiji Indonesian Pharmaceutical Industries.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fradiomycin + gramicidin.